Covalent cross‐linking of vasoactive intestinal peptide (VIP) to its receptor in intact colonic adenocarcinoma cells in culture (HT 29)

Open Access
Publisher Website
Google Scholar
Abstract
[1 2 5I]Monoiodinated vasoactive intestinal peptide (125I‐VIP) was cross‐linked with human colonic adenocarcinoma cells (HT 29 cells) grown as a monolayer using dithiobis(succinimidylpropionate) as cross‐linking reagent. The cross‐linked polypeptides were separated by polyacrylamide gel electrophoresis in the presence of sodium dodecyl sulfate.A major polypeptide of Mr= 67000 was characterized and it behaved like a high‐affinity binding site for VIP according to the following data. The concentration of native VIP (0.5 nM) giving half‐maximum inhibition of 125I‐VIP covalent cross‐linking with this polypeptide was very similar to that giving half‐maximum displacement of 125I‐VIP on HT 29 cells (0.6 nM). Glucagon or insulin was unable to inhibit the labelling of the Mr‐67000 component. In our experimental conditions neither specific 125I‐VIP binding nor covalent labelling was observed with monolayers of Madin Darby canine kidney epithelial cells (MDCK cells) or African green monkey kidney fibroblasts (Vero cells) while the Mr‐67000 polypeptide was also characterized with human rectal adenocarcinoma cells (HRT 18 cells), known to possess the VIP receptor. Preincubation of HT 29 cells with native VIP at 37°C, before 125I‐VIP binding and subsequent crosslinking reaction, decreased the labelling of the Mr‐67000 polypeptide up to 80%. Assuming one molecule of 125I‐VIP cross‐linked per polypeptide, we have characterized, for the first time, a major polypeptide of Mr= 64000, which belongs to the high‐affinity VIP binding site of an intestinal human cell line.

This publication has 31 references indexed in Scilit: